Literature DB >> 9563801

Decreased expression and release of dipeptidyl peptidase IV (CD26) in cultured peripheral blood T lymphocytes of oral cancer patients.

T Uematsu1, M Urade, M Yamaoka.   

Abstract

To investigate the mechanism whereby serum dipeptidyl peptidase (DPP) IV activity in oral cancer patients is decreased, we examined the expression of cell surface DPP IV, also known as CD26, in cultured peripheral blood T lymphocytes of these patients and the amounts of DPP IV released into culture medium; values were compared with those found in healthy subjects. When peripheral blood T lymphocytes were cultured in the presence of phytohemagglutinin, concanavalin A and/or interleukin-2, the proliferative response and expression of CD26 (DPP IV) in their plasma membranes were greatly diminished in oral cancer patients as compared with those in healthy subjects. In addition, DPP IV activity in lymphocyte culture medium was reduced more in oral cancer patients than in healthy subjects, indicating decreased shedding of DPP IV from activated T lymphocytes in the patients. Based on these findings, it is suggested that suppression of DPP IV expression in peripheral blood T lymphocytes is one of the important factors involved in the mechanism of decrease of serum DPP IV activity in oral cancer patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563801     DOI: 10.1111/j.1600-0714.1998.tb01924.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  4 in total

1.  Potential of soluble CD26 as a serum marker for colorectal cancer detection.

Authors:  Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal
Journal:  World J Clin Oncol       Date:  2011-06-10

2.  Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer.

Authors:  O J Cordero; D Ayude; M Nogueira; F J Rodriguez-Berrocal; M P de la Cadena
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

3.  Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker.

Authors:  Virginia Boccardi; Luigi Marano; Rosaria Rita Amalia Rossetti; Maria Rosaria Rizzo; Natale di Martino; Giuseppe Paolisso
Journal:  BMC Cancer       Date:  2015-10-15       Impact factor: 4.430

Review 4.  CD26 and Asthma: a Comprehensive Review.

Authors:  Juan J Nieto-Fontarigo; Francisco J González-Barcala; Esther San José; Pilar Arias; Montserrat Nogueira; Francisco J Salgado
Journal:  Clin Rev Allergy Immunol       Date:  2019-04       Impact factor: 8.667

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.